Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia
The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia...
Gespeichert in:
| Veröffentlicht in: | Journal of radiation research 2016-01, Vol.57 (1), p.44-49 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | 1 |
| container_start_page | 44 |
| container_title | Journal of radiation research |
| container_volume | 57 |
| creator | Ohno, Tatsuya Wakatsuki, Masaru Thinh, Dang Huy Quoc Tung, Ngo Thanh Erawati, Dyah Supriana, Nana Beena Devi, C.R. Kato, Shingo Thephamongkhol, Kullathorn Chansilpa, Yaowalak Calaguas, Miriam Joy C. Xiaoting, Xu Jianping, Cao Banu, Parvin Akhter Cho, Chul-Koo Karasawa, Kumiko Nakano, Takashi Tsujii, Hirohiko |
| description | The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m2). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3–4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis–free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes. |
| doi_str_mv | 10.1093/jrr/rrv046 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4708910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jrr/rrv046</oup_id><sourcerecordid>10.1093/jrr/rrv046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-3a3a1c243910e708d999e5e5d6fa6c6e59008435e5c0df9d5964826fca16562b3</originalsourceid><addsrcrecordid>eNp9kc9KxDAQxoMouq5efADJxYuwOmn-bONBkMV_IHrRc4lp6kbapExbwZtP4MU39EmMuyp68TTDzDe_L-EjZIfBAQPNDx8RDxGfQKgVMmJc6IlmcrpKRiBSz0HBBtnsukeAbAoS1slGpjIphMxH5HUWgx0QXeipnbsmoil97OcOTftMq4j0lr-_vAlqQkmvIbWMBtPFdm7wOTw4U1NrgnV4RE86bwJthrr3NuEc0h592seKJh49izg0C-L1YGtnkM5ibJNP72OgPizut8haZerObX_VMbk7O72dXUyubs4vZydXEytZ3k-44YbZTHDNwE0hL7XWTjpZqsooq5zUALngaWKhrHQptRJ5piprmJIqu-djcrzktsN948rP96KpixZ9k_5VROOLv5vg58VDfCpEckumCbC_BFiMXYeu-rllUHymUqRUimUqSbz72-1H-h1DEuwtBXFo_wN9ALh5mv8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Ohno, Tatsuya ; Wakatsuki, Masaru ; Thinh, Dang Huy Quoc ; Tung, Ngo Thanh ; Erawati, Dyah ; Supriana, Nana ; Beena Devi, C.R. ; Kato, Shingo ; Thephamongkhol, Kullathorn ; Chansilpa, Yaowalak ; Calaguas, Miriam Joy C. ; Xiaoting, Xu ; Jianping, Cao ; Banu, Parvin Akhter ; Cho, Chul-Koo ; Karasawa, Kumiko ; Nakano, Takashi ; Tsujii, Hirohiko</creator><creatorcontrib>Ohno, Tatsuya ; Wakatsuki, Masaru ; Thinh, Dang Huy Quoc ; Tung, Ngo Thanh ; Erawati, Dyah ; Supriana, Nana ; Beena Devi, C.R. ; Kato, Shingo ; Thephamongkhol, Kullathorn ; Chansilpa, Yaowalak ; Calaguas, Miriam Joy C. ; Xiaoting, Xu ; Jianping, Cao ; Banu, Parvin Akhter ; Cho, Chul-Koo ; Karasawa, Kumiko ; Nakano, Takashi ; Tsujii, Hirohiko</creatorcontrib><description>The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m2). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3–4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis–free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.</description><identifier>ISSN: 0449-3060</identifier><identifier>EISSN: 1349-9157</identifier><identifier>DOI: 10.1093/jrr/rrv046</identifier><identifier>PMID: 26254458</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Aged ; Asia ; Carcinoma ; Chemoradiotherapy - adverse effects ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma ; Nasopharyngeal Neoplasms - pathology ; Nasopharyngeal Neoplasms - therapy ; Neoplasm Staging ; Oncology ; Patient Compliance ; Treatment Outcome</subject><ispartof>Journal of radiation research, 2016-01, Vol.57 (1), p.44-49</ispartof><rights>The Author 2015. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. 2015</rights><rights>The Author 2015. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-3a3a1c243910e708d999e5e5d6fa6c6e59008435e5c0df9d5964826fca16562b3</citedby><cites>FETCH-LOGICAL-c518t-3a3a1c243910e708d999e5e5d6fa6c6e59008435e5c0df9d5964826fca16562b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708910/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708910/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,1599,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26254458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohno, Tatsuya</creatorcontrib><creatorcontrib>Wakatsuki, Masaru</creatorcontrib><creatorcontrib>Thinh, Dang Huy Quoc</creatorcontrib><creatorcontrib>Tung, Ngo Thanh</creatorcontrib><creatorcontrib>Erawati, Dyah</creatorcontrib><creatorcontrib>Supriana, Nana</creatorcontrib><creatorcontrib>Beena Devi, C.R.</creatorcontrib><creatorcontrib>Kato, Shingo</creatorcontrib><creatorcontrib>Thephamongkhol, Kullathorn</creatorcontrib><creatorcontrib>Chansilpa, Yaowalak</creatorcontrib><creatorcontrib>Calaguas, Miriam Joy C.</creatorcontrib><creatorcontrib>Xiaoting, Xu</creatorcontrib><creatorcontrib>Jianping, Cao</creatorcontrib><creatorcontrib>Banu, Parvin Akhter</creatorcontrib><creatorcontrib>Cho, Chul-Koo</creatorcontrib><creatorcontrib>Karasawa, Kumiko</creatorcontrib><creatorcontrib>Nakano, Takashi</creatorcontrib><creatorcontrib>Tsujii, Hirohiko</creatorcontrib><title>Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia</title><title>Journal of radiation research</title><addtitle>J Radiat Res</addtitle><description>The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m2). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3–4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis–free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.</description><subject>Adult</subject><subject>Aged</subject><subject>Asia</subject><subject>Carcinoma</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasopharyngeal Carcinoma</subject><subject>Nasopharyngeal Neoplasms - pathology</subject><subject>Nasopharyngeal Neoplasms - therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Patient Compliance</subject><subject>Treatment Outcome</subject><issn>0449-3060</issn><issn>1349-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc9KxDAQxoMouq5efADJxYuwOmn-bONBkMV_IHrRc4lp6kbapExbwZtP4MU39EmMuyp68TTDzDe_L-EjZIfBAQPNDx8RDxGfQKgVMmJc6IlmcrpKRiBSz0HBBtnsukeAbAoS1slGpjIphMxH5HUWgx0QXeipnbsmoil97OcOTftMq4j0lr-_vAlqQkmvIbWMBtPFdm7wOTw4U1NrgnV4RE86bwJthrr3NuEc0h592seKJh49izg0C-L1YGtnkM5ibJNP72OgPizut8haZerObX_VMbk7O72dXUyubs4vZydXEytZ3k-44YbZTHDNwE0hL7XWTjpZqsooq5zUALngaWKhrHQptRJ5piprmJIqu-djcrzktsN948rP96KpixZ9k_5VROOLv5vg58VDfCpEckumCbC_BFiMXYeu-rllUHymUqRUimUqSbz72-1H-h1DEuwtBXFo_wN9ALh5mv8</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Ohno, Tatsuya</creator><creator>Wakatsuki, Masaru</creator><creator>Thinh, Dang Huy Quoc</creator><creator>Tung, Ngo Thanh</creator><creator>Erawati, Dyah</creator><creator>Supriana, Nana</creator><creator>Beena Devi, C.R.</creator><creator>Kato, Shingo</creator><creator>Thephamongkhol, Kullathorn</creator><creator>Chansilpa, Yaowalak</creator><creator>Calaguas, Miriam Joy C.</creator><creator>Xiaoting, Xu</creator><creator>Jianping, Cao</creator><creator>Banu, Parvin Akhter</creator><creator>Cho, Chul-Koo</creator><creator>Karasawa, Kumiko</creator><creator>Nakano, Takashi</creator><creator>Tsujii, Hirohiko</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia</title><author>Ohno, Tatsuya ; Wakatsuki, Masaru ; Thinh, Dang Huy Quoc ; Tung, Ngo Thanh ; Erawati, Dyah ; Supriana, Nana ; Beena Devi, C.R. ; Kato, Shingo ; Thephamongkhol, Kullathorn ; Chansilpa, Yaowalak ; Calaguas, Miriam Joy C. ; Xiaoting, Xu ; Jianping, Cao ; Banu, Parvin Akhter ; Cho, Chul-Koo ; Karasawa, Kumiko ; Nakano, Takashi ; Tsujii, Hirohiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-3a3a1c243910e708d999e5e5d6fa6c6e59008435e5c0df9d5964826fca16562b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Asia</topic><topic>Carcinoma</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasopharyngeal Carcinoma</topic><topic>Nasopharyngeal Neoplasms - pathology</topic><topic>Nasopharyngeal Neoplasms - therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Patient Compliance</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohno, Tatsuya</creatorcontrib><creatorcontrib>Wakatsuki, Masaru</creatorcontrib><creatorcontrib>Thinh, Dang Huy Quoc</creatorcontrib><creatorcontrib>Tung, Ngo Thanh</creatorcontrib><creatorcontrib>Erawati, Dyah</creatorcontrib><creatorcontrib>Supriana, Nana</creatorcontrib><creatorcontrib>Beena Devi, C.R.</creatorcontrib><creatorcontrib>Kato, Shingo</creatorcontrib><creatorcontrib>Thephamongkhol, Kullathorn</creatorcontrib><creatorcontrib>Chansilpa, Yaowalak</creatorcontrib><creatorcontrib>Calaguas, Miriam Joy C.</creatorcontrib><creatorcontrib>Xiaoting, Xu</creatorcontrib><creatorcontrib>Jianping, Cao</creatorcontrib><creatorcontrib>Banu, Parvin Akhter</creatorcontrib><creatorcontrib>Cho, Chul-Koo</creatorcontrib><creatorcontrib>Karasawa, Kumiko</creatorcontrib><creatorcontrib>Nakano, Takashi</creatorcontrib><creatorcontrib>Tsujii, Hirohiko</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of radiation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohno, Tatsuya</au><au>Wakatsuki, Masaru</au><au>Thinh, Dang Huy Quoc</au><au>Tung, Ngo Thanh</au><au>Erawati, Dyah</au><au>Supriana, Nana</au><au>Beena Devi, C.R.</au><au>Kato, Shingo</au><au>Thephamongkhol, Kullathorn</au><au>Chansilpa, Yaowalak</au><au>Calaguas, Miriam Joy C.</au><au>Xiaoting, Xu</au><au>Jianping, Cao</au><au>Banu, Parvin Akhter</au><au>Cho, Chul-Koo</au><au>Karasawa, Kumiko</au><au>Nakano, Takashi</au><au>Tsujii, Hirohiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia</atitle><jtitle>Journal of radiation research</jtitle><addtitle>J Radiat Res</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>57</volume><issue>1</issue><spage>44</spage><epage>49</epage><pages>44-49</pages><issn>0449-3060</issn><eissn>1349-9157</eissn><abstract>The aim of this study was to evaluate the toxicity and efficacy of radiotherapy concurrent with weekly cisplatin for T3–4 and N0–1 nasopharyngeal cancer. Between 2005 and 2010, 70 patients with nasopharyngeal cancer (T3–4 N0–1 M0, World Health Organization Type 2–3) from Vietnam, Indonesia, Malaysia and Thailand were registered. Patients were treated with 2D radiotherapy concurrent with weekly cisplatin (30 mg/m2). Neither adjuvant nor induction chemotherapy was given. Ninety-three percent of the patients completed at least four cycles of weekly cisplatin during radiotherapy. The median total doses for the primary tumor and positive lymph nodes were 70 and 66 Gy, respectively. The median overall treatment time of concurrent chemoradiotherapy was 52 days. No treatment-related deaths occurred. Grade 3–4 acute toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of patients, respectively. With a median follow-up time of 52 months for the 40 surviving patients, the 3-year local control, locoregional tumor control, distant metastasis–free survival and overall survival rates were 80%, 75%, 74% and 80%, respectively. In conclusion, the current results illustrate that our concurrent chemoradiotherapy regimen was feasible, but disease control remained insufficient. Further research is encouraged in order to improve clinical outcomes.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>26254458</pmid><doi>10.1093/jrr/rrv046</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0449-3060 |
| ispartof | Journal of radiation research, 2016-01, Vol.57 (1), p.44-49 |
| issn | 0449-3060 1349-9157 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4708910 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Adult Aged Asia Carcinoma Chemoradiotherapy - adverse effects Disease-Free Survival Female Humans Male Middle Aged Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms - pathology Nasopharyngeal Neoplasms - therapy Neoplasm Staging Oncology Patient Compliance Treatment Outcome |
| title | Concurrent chemoradiotherapy for T3–4 and N0–1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A04%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concurrent%20chemoradiotherapy%20for%20T3%E2%80%934%20and%20N0%E2%80%931%20nasopharyngeal%20cancer:%20Asian%20multicenter%20trial%20of%20the%20Forum%20for%20Nuclear%20Cooperation%20in%20Asia&rft.jtitle=Journal%20of%20radiation%20research&rft.au=Ohno,%20Tatsuya&rft.date=2016-01-01&rft.volume=57&rft.issue=1&rft.spage=44&rft.epage=49&rft.pages=44-49&rft.issn=0449-3060&rft.eissn=1349-9157&rft_id=info:doi/10.1093/jrr/rrv046&rft_dat=%3Coup_pubme%3E10.1093/jrr/rrv046%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26254458&rft_oup_id=10.1093/jrr/rrv046&rfr_iscdi=true |